Efficacy News and Research

RSS

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Patients with advanced chronic lymphocytic leukemia often receive donor transplants that effectively "reboot" their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the transplanted immune cells may also harm normal tissues, causing graft-versus-host disease.

7 Aug 2013

UCLA researchers combine cellular and gene therapies to develop treatment for breast cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to a patient's brain.

7 Aug 2013

Researchers improve efficacy of RASV by modifying pathogen’s ability to survive in hostile environment

The bacterial pathogen Salmonella has a notorious capacity for infection. Last year alone, according to the Center for Disease Control, various species of Salmonella caused multistate disease outbreaks linked with contaminated peanut butter, mangoes, ground beef, cantaloupe, poultry, tuna fish, small turtles and dry dog food.

7 Aug 2013

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

A team of scientists, led by Napoleone Ferrara, MD, has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.

6 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.

3 Aug 2013

Jersey Shore hospital participates in clinical study of investigational vaccine for prevention of CDI

Mark Martens, M.D., chief of Obstetrics and Gynecology at Jersey Shore University Medical Center, announces that the hospital is participating in a clinical study to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI).

3 Aug 2013

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

Clinicians should be aware of use of herbal supplements while breastfeeding

In an article published in this month's issue of Pediatrics In Review, researchers from Boston University School of Medicine (BUSM) stress the importance of physicians recognizing that many mothers use herbal supplements while breastfeeding in order to make accurate health assessments for both mother and child.

2 Aug 2013

Microbiologists identify staph-killing compound that may be effective for osteomyelitis

Osteomyelitis, a debilitating bone infection most frequently caused by Staphylococcus aureus ("staph") bacteria, is particularly challenging to treat.

2 Aug 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company's x (IND) application has been accepted by the US FDA and is now active.

2 Aug 2013

UCLA researchers develop treatment approach for breast cancer metastasized to brain

Researchers at UCLA's Jonsson Comprehensive Cancer Center (JCCC) have successfully combined cellular therapy and gene therapy in a mouse model system to develop a viable treatment strategy for breast cancer that has metastasized, or spread, to the patient's brain.

2 Aug 2013

August edition of NPS RADAR includes reviews for new medicines listed on PBS

The 10th anniversary edition of NPS RADAR contains reviews for new medicines listed on the Pharmaceutical Benefits Scheme including rivaroxaban (Xarelto), rotigotine patches (Neupro) and mifepristone (Mifepristone Linepharma) followed by misoprostol (GyMiso).

1 Aug 2013

Boehringer Ingelheim, Lilly initiate linagliptin clinical trial in adults with Type 2 Diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta).

1 Aug 2013

Viropharma announces financial results for second quarter of 2013

VIROPHARMA INCORPORATED (Nasdaq: VPHM) today announced financial results for the second quarter of 2013. Net sales were $104 million for the second quarter ended June 30, 2013 as compared to $95 million in the comparative period of 2012.

1 Aug 2013

Novocure uses NovoTTF therapy to treat first recurrent glioblastoma tumor patient

Novocure today announced that Dr. Tatsunori Okamaura, MD, Ph.D., of the Kashiwaba Neurosurgical Hospital in Sapporo, Japan has treated the first patient in Japan with alternating electric field therapy.

1 Aug 2013

Pharmanest announces positive results from SHACT Phase II study

Karolinska Development: Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest.

1 Aug 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.

1 Aug 2013

Efficacy News and Research

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

UCLA researchers combine cellular and gene therapies to develop treatment for breast cancer

Researchers improve efficacy of RASV by modifying pathogen’s ability to survive in hostile environment

Ensemble Therapeutics initiates research and development collaboration with Novartis

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Jersey Shore hospital participates in clinical study of investigational vaccine for prevention of CDI

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Clinicians should be aware of use of herbal supplements while breastfeeding

Microbiologists identify staph-killing compound that may be effective for osteomyelitis

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

UCLA researchers develop treatment approach for breast cancer metastasized to brain

August edition of NPS RADAR includes reviews for new medicines listed on PBS

Boehringer Ingelheim, Lilly initiate linagliptin clinical trial in adults with Type 2 Diabetes

Viropharma announces financial results for second quarter of 2013

Novocure uses NovoTTF therapy to treat first recurrent glioblastoma tumor patient

Pharmanest announces positive results from SHACT Phase II study

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News